- Home
- NRXS vs HKPD Comparison
NRXS vs HKPD Comparison
Compare NRXS & HKPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRXS
- HKPD
- Stock Information
- Founded
- NRXS 2011
- HKPD 2016
- Country
- NRXS United States
- HKPD Hong Kong
- Employees
- NRXS N/A
- HKPD N/A
- Industry
- NRXS
- HKPD Other Pharmaceuticals
- Sector
- NRXS
- HKPD Health Care
- Exchange
- NRXS Nasdaq
- HKPD Nasdaq
- Market Cap
- NRXS 25.8M
- HKPD 20.9M
- IPO Year
- NRXS 2023
- HKPD 2025
- Fundamental
- Price
- NRXS $2.99
- HKPD $1.42
- Analyst Decision
- NRXS Strong Buy
- HKPD
- Analyst Count
- NRXS 1
- HKPD 0
- Target Price
- NRXS $7.00
- HKPD N/A
- AVG Volume (30 Days)
- NRXS 1.0M
- HKPD 183.7K
- Earning Date
- NRXS 11-12-2025
- HKPD 08-14-2025
- Dividend Yield
- NRXS N/A
- HKPD N/A
- EPS Growth
- NRXS N/A
- HKPD N/A
- EPS
- NRXS N/A
- HKPD N/A
- Revenue
- NRXS $3,217,531.00
- HKPD $20,313,818.00
- Revenue This Year
- NRXS $62.14
- HKPD N/A
- Revenue Next Year
- NRXS $131.87
- HKPD N/A
- P/E Ratio
- NRXS N/A
- HKPD N/A
- Revenue Growth
- NRXS 41.93
- HKPD 21.72
- 52 Week Low
- NRXS $1.33
- HKPD $0.81
- 52 Week High
- NRXS $6.20
- HKPD $3.79
- Technical
- Relative Strength Index (RSI)
- NRXS 45.67
- HKPD 53.76
- Support Level
- NRXS $2.94
- HKPD $1.34
- Resistance Level
- NRXS $3.96
- HKPD $1.53
- Average True Range (ATR)
- NRXS 0.31
- HKPD 0.13
- MACD
- NRXS -0.06
- HKPD 0.02
- Stochastic Oscillator
- NRXS 12.61
- HKPD 54.32
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
About HKPD Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares
Hong Kong Pharma Digital Technology Holdings Ltd operates in two main categories: (i) OTC pharmaceutical cross-border e-commerce supply chain services, conducted through its Hong Kong subsidiary, Joint Cross Border, which it refers to as the Supply Chain Services division, and (ii) OTC pharmaceutical cross-border procurement and distribution, conducted through its Hong Kong subsidiary, V-Alliance, which it referred to as the Procurement and Distribution division. Based in Hong Kong, Joint Cross Border has established itself as a provider of third-party supply chain services in Mainland China's OTC pharmaceutical cross-border e-commerce market.